World Lung 2019 – Astra’s achievement in SCLC unlikely to be a game changer
Astrazeneca has scored a hit with Imfinzi in the Caspian trial, but the results are unlikely to endanger Roche's Tecentriq.
World Lung 2019 – Oncimmune’s liquid biopsy hits in large trial
The data are positive, but might not do much for the company’s sales.
World Lung 2019 – Amgen tries to keep the pace in Kras chase
The latest cut of data from a trial of Amgen’s closely watched Kras inhibitor AMG 510 contains more encouraging signals in lung cancer, though some of the loftiest hopes…
Esmo 2019 preview – Parps on parade
Among small-molecule approaches Europe’s premier oncology conference gives star billing to three Parp inhibitors in ovarian cancer.
ESC 2019 – Amarin hopes for guideline boost despite regulatory delay
Amarin is plugging a change in ESC guidelines to include Vascepa, but with the product’s regulatory fate undecided how much difference will this make to sales?
Vantage ESC 2019 roundup
A collection of all of Vantage's coverage from the 2019 European Society of Cardiology meeting.
ESC 2019 – Carmat is stout-hearted in the face of a challenging schedule
Carmat says its artificial heart is the best such device in existence. But time is short, and so is money.
ESC 2019 – Medicines Company impresses with inclisiran
With decent efficacy and clean safety in the Orion-11 trial, questions now turn to pricing and whether The Medicines Company will be taken out.
ESC 2019 – Astra’s latest Brilinta hopes bleed out on full Themis data
An increased risk of bleeding outweighs Brilinta’s benefits in a primary prevention population, but there might be a way forward in a patient subgroup.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.